15 Jul What Pharmaceutical Companies Should Know Before Expanding Into International Markets
Expanding a pharmaceutical business into new international markets is one of the most promising ways to grow revenue and reach patients who need treatments that are not yet available where they live. It is also one of the most complicated types of expansion a company can attempt. Pharmaceutical products are held to a different standard than nearly any other category of goods, and every country a company enters brings its own regulatory framework, documentation requirements, and approval timelines.
Companies that plan carefully before expanding tend to move faster and avoid costly setbacks. Companies that treat international expansion as a simple logistics exercise often run into problems that could have been avoided with proper preparation. Here is what pharmaceutical companies should understand before taking their products into new markets, explained in enough detail to actually help with planning. The regulatory complexity involved in global submissions is also explored in this overview of how pharmaceutical companies support global regulatory submissions through specialized testing.
1. Regulatory Approval Requirements Vary Significantly by Country
Every country has its own regulatory body responsible for approving pharmaceutical products before they can be sold or distributed. The United States relies on the FDA. The European Union has the European Medicines Agency, along with country-specific agencies for certain approvals. Countries across Asia, Latin America, and the Middle East each have their own equivalent bodies, and each one has different standards for what evidence is required, how long review takes, and what ongoing compliance looks like after approval.
This means a product that has been approved in one country cannot simply be sold in another without going through that country’s own approval process. Some regulators accept certain foreign approvals as supporting evidence, which can speed up their own review. Others require a company to start from scratch with local clinical data. Understanding which category a target market falls into early in the planning process helps a company build a realistic timeline rather than guessing and being surprised later.
2. Clinical Trial Data May Not Transfer Automatically
Many countries require clinical trial data collected specifically within their own population, even if a drug has already gone through extensive trials elsewhere. Two realities shape how companies need to plan for this.
Population differences can affect approval: Genetic variation, diet, and other population-level factors can change how a drug performs in practice, which is why regulators in a new market may not accept trial data collected elsewhere. The required response also varies by country: In some cases, a smaller bridging study is enough to satisfy local regulators. In others, a full local clinical trial is required before approval can move forward.
Companies should budget both time and money for this possibility rather than assuming existing trial data will be accepted everywhere. Knowing which situation applies to a specific target market, and building that into the overall expansion timeline, prevents a company from promising a launch date that regulatory reality will not allow.
3. Import and Export Compliance Is a Distinct Challenge
Beyond the regulatory approval of the product itself, pharmaceutical companies need to navigate the customs and import compliance requirements of each country they enter. This includes proper classification of products under each country’s tariff codes, documentation of ingredients and manufacturing processes, cold chain compliance for temperature sensitive products, and country-specific labeling requirements.
Many pharmaceutical companies address this challenge by using customs brokerage with Livingston to access jurisdiction-specific expertise in product classification, documentation, and cold chain compliance without having to build this knowledge internally for every new market they enter.
Failure to meet these requirements can lead to customs delays, financial penalties, or even the loss of valuable pharmaceutical shipments. For products that are sensitive to both time and temperature, a delay at the border can have serious consequences. If a shipment remains held while documentation issues are resolved, it may exceed its approved temperature range and become unusable, resulting in product waste and significant financial losses.
4. Intellectual Property Protection Differs by Region
Patent protection is not universal. A pharmaceutical company that holds a strong patent position in its home market may find that protection is weaker, shorter, or structured differently in a new market. Some countries have compulsory licensing provisions that allow local manufacturers to produce a patented drug under certain conditions, typically related to public health emergencies or affordability concerns.
Before expanding, companies should have their intellectual property counsel review the patent landscape in each target market specifically. This includes understanding how long patent protection will last locally, whether any generic competitors are positioned to enter once protection ends, and whether the country has a history of enforcing patent rights consistently. This research shapes both the timeline and the long-term revenue expectations for the expansion.
5. Pricing and Reimbursement Systems Require Local Expertise
How a drug gets priced and reimbursed varies enormously across countries. Some markets have government-run health systems that negotiate drug prices centrally. Others rely heavily on private insurance with a more market-driven approach to pricing. Many countries require a health technology assessment, which evaluates the cost effectiveness of a treatment compared to existing options before it can be included in reimbursement programs.
Companies that do not understand these systems risk setting a price that either fails to gain approval for reimbursement or leaves significant revenue on the table. Local market access consultants, who specialize in navigating pricing and reimbursement in specific countries, are often a worthwhile investment early in the process rather than something to figure out after the product has already launched.
6. Distribution Infrastructure Needs Careful Planning
Getting a pharmaceutical product from manufacturing facility to patient involves a distribution chain that must maintain quality standards throughout. Two things matter most when planning this for a new market.
Cold chain reliability is especially critical for biologics, vaccines, and other products that require consistent temperature control from the point of manufacture through to the pharmacy or hospital. Local distribution relationships also matter significantly — companies need to evaluate whether existing partners can support the new market, or whether new relationships need to be established with distributors who understand the country’s healthcare infrastructure and pharmacy networks.
This planning should happen well before regulatory approval is finalized, since building reliable distribution relationships often takes just as long as the regulatory process itself.
7. The Financial Investment Is Often Larger Than Expected
International expansion in the pharmaceutical industry is capital intensive. Regulatory submissions, potential local clinical trials, distribution setup, market access consulting, and compliance infrastructure all require significant investment before a company sees meaningful revenue from a new market. According to the International Federation of Pharmaceutical Manufacturers and Associations, global pharmaceutical growth is increasingly driven by international markets, making global expansion a key strategy despite the costs involved.
Companies that plan their budget realistically, accounting for regulatory delays, additional trial requirements, and distribution setup costs, are in a much stronger position than those that underestimate the investment required and run into cash flow problems partway through the expansion process.
Final Thoughts
Expanding into international markets offers pharmaceutical companies real opportunities for growth and the chance to bring treatments to patients who need them in places where they were not previously available. The companies that succeed at this kind of expansion are the ones that plan thoroughly across every dimension of the process — from regulatory approval and clinical data requirements to customs compliance, intellectual property protection, pricing systems, and distribution infrastructure.
None of these challenges are reasons to avoid international expansion. They are simply the reality of operating in a heavily regulated global industry, and they are entirely manageable with the right planning and the right partners. Companies that take the time to understand each of these areas before committing to a launch timeline consistently see smoother expansions, fewer costly surprises, and stronger long-term results in the markets they enter.
Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on July 15, 2026 by Marie Benz MD FAAD